Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Cash & Equivalents (2016 - 2025)

Standard Biotools (LAB) has disclosed Cash & Equivalents for 16 consecutive years, with $120.9 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 27.51% to $120.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $120.9 million through Dec 2025, down 27.51% year-over-year, with the annual reading at $120.9 million for FY2025, 27.51% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $120.9 million at Standard Biotools, down from $129.4 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $288.3 million in Q1 2024, with the low at $29.5 million in Q4 2021.
  • Average Cash & Equivalents over 5 years is $114.0 million, with a median of $98.4 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents tumbled 58.66% in 2021, then skyrocketed 269.23% in 2023.
  • Over 5 years, Cash & Equivalents stood at $29.5 million in 2021, then soared by 179.38% to $82.3 million in 2022, then plummeted by 36.23% to $52.5 million in 2023, then surged by 217.58% to $166.7 million in 2024, then fell by 27.51% to $120.9 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $120.9 million, $129.4 million, and $158.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.